Company Description
23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally.
The company operates in two segments, Consumer and Research Services, and Therapeutics. The Consumer and Research Services segment provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.
This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services.
The Therapeutics segment focuses on the development of novel therapies; and research and development of programs in various therapeutic areas, such as oncology, immunological and inflammatory diseases, and other disease areas, as well as engages in the out-licensing of intellectual property associated with identified drug targets and expenses related to the discovery and development of therapeutic product candidates.
This segment also comprises a therapeutics product portfolio, including 23ME-00610 (P006), a humanized monoclonal antibody that interfere with the ability of CD200R1 to interact with CD200 in cancer cells; GSK6097608, an immuno-oncology program for targeting CD96; and 23ME-01473 is an immuno-oncology antibody program that targets the ULBP6 proteins in the NKG2D pathway.
The company has collaboration with Mirador Therapeutics to advance mirador’s precision medicines for immunology and inflammation.
23andMe Holding Co. was founded in 2006 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2006 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 582 |
| CEO | Anne Wojcicki |
Contact Details
Address: 349 Oyster Point Boulevard South San Francisco, California 94080 United States | |
| Phone | 650 938 6300 |
| Website | 23andme.com |
Stock Details
| Ticker Symbol | ME |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001804591 |
| CUSIP Number | 90138Q108 |
| ISIN Number | US90138Q1085 |
| Employer ID | 87-1240344 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Anne Wojcicki | Co-Founder, Chief Executive Officer, President and Chair of the Board |
| Joseph Selsavage | Chief Financial and Accounting Officer |
| Eli Fry | Vice President of Operations |
| Guy Chayoun | Vice President, Interim General Counsel and Corporate Secretary |
| Katie Watson | Vice President of Communications |
| Jonathan Ward | Chief Marketing Officer |
| Savita Pillai | Vice President of People |
| Dr. Jennifer Low M.D., Ph.D. | Head of Therapeutics Development |
| Kent Hillyer | Vice President of Consumer Operations |
| Daniel Chu | Chief Product Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 15, 2024 | 144 | Filing |
| Nov 15, 2024 | 144 | Filing |
| Nov 15, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 15, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 15, 2024 | 144 | Filing |
| Nov 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 4, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |